Ayedh Alamri
Cardiovascular Disease · Boston, MANPI 1124625124
Payments from drug & device makers
Across 98 payments — averaging $31.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$467
- Amgen$332
- Abiomed$285
- United Therapeutics Corporation$232
- AstraZeneca$223
- Actelion Pharmaceuticals US, Inc.$168
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $467 |
| Amgen | 9 | $332 |
| Abiomed | 4 | $285 |
| United Therapeutics Corporation | 2 | $232 |
| AstraZeneca | 11 | $223 |
| Actelion Pharmaceuticals US, Inc. | 6 | $168 |
| Boehringer Ingelheim | 6 | $166 |
| Alnylam Pharmaceuticals Inc. | 7 | $156 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $146 |
| Penumbra, Inc. | 1 | $143 |
| Angiodynamics, Inc. | 2 | $114 |
| Bayer | 6 | $111 |
| Boston Scientific | 2 | $108 |
| E.r. Squibb & Sons, L.L.C. | 3 | $88 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $87 |
| Daiichi Sankyo Inc. | 3 | $77 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $49 |
| Merck | 3 | $47 |
| Lantheus Medical Imaging, Inc. | 1 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Shockwave Medical, Inc | 1 | $23 |
| Asahi Intecc USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$143
- Repatha$137
- TYVASO$123
- ORENITRAM$109
How this compares
$3,094 in reported general payments places this provider in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 14 | $127 |
| Amlodipine Besylate | 14 | $79 |
| Furosemide | 17 | $54 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$31.2M
- Stephen WiviottBoston$29.2M
- David MorrowBoston$19M
- Scott SolomonBoston$16.2M
- Paul RidkerBoston$16.2M
- Mohit JainBoston$13M
- Calum MacraeBoston$11.4M
- Benjamin SciricaBoston$11.3M
- Robert GiuglianoBoston$10.5M
- Erin BohulaBoston$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.